SAB Biotherapeutics, Inc. (SABSW)
- Previous Close
0.0226 - Open
0.0329 - Bid --
- Ask --
- Day's Range
0.0226 - 0.0226 - 52 Week Range
0.0226 - 0.0226 - Volume
1,559 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
0.08 - EPS (TTM)
0.2920 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
www.sabbiotherapeutics.comRecent News: SABSW
View More
Compare To: SABSW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SABSW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.86%
Return on Equity (ttm)
-81.92%
Revenue (ttm)
1.32M
Net Income Avi to Common (ttm)
-34.11M
Diluted EPS (ttm)
0.2920
Balance Sheet and Cash Flow
Total Cash (mrq)
20.76M
Total Debt/Equity (mrq)
17.98%
Levered Free Cash Flow (ttm)
-22.1M